Do you utilize Oncotype Dx or other multigene assays to guide adjuvant chemotherapy for ER+ HER2- breast cancers that are pT3N0?

Size matters when it comes to prognosis, but biology matters more when it comes to prediction of chemotherapy benefit. Evidence for the prospective Plan B trial indicating good prognosis in patients with high risk node-negative and 1-3 node-positive ER+, HER2- breast cancer with endocrine therapy al...